NICE IDs

11/10/2021

ID1553: Cenobamate for focal onset seizures in epilepsy

11/10/2021

ID3802: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

11/10/2021

ID3734: Tralokinumab for treating moderate to severe atopic dermatitis

11/10/2021

ID2722: Belimumab for treating lupus nephritis

11/10/2021

ID1624: Berotralstat for preventing acute attacks of hereditary angioedema

11/10/2021

ID2731: Vericiguat for treating chronic heart failure with reduced ejection fraction

11/10/2021

ID1090: Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies

11/10/2021

ID3892: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy

11/10/2021

ID2731: Vericiguat for treating chronic heart failure with reduced ejection fraction

11/10/2021

ID1083: Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia

11/10/2021

ID1557: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies

11/10/2021

ID2727: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

11/10/2021

ID1087: Fostamatinib for treating persistent or chronic immune thrombocytopenia

11/10/2021

ID1393: Ponesimod for treating relapsing multiple sclerosis

11/10/2021

ID1573: Midostaurin for treating advanced systemic mastocytosis

11/10/2021

ID3826: Empagliflozin for treating chronic heart failure with reduced ejection fraction

11/10/2021

ID3741: Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer

11/10/2021

ID3866: Dapagliflozin for treating chronic kidney disease

11/10/2021

ID2692: Bimekizumab for treating moderate to severe chronic plaque psoriasis

11/10/2021

ID1620: Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma